GLP-1 Patents Generate $60 Billion, Deepening a 100 Million-Person U.S. Treatment Gap
Updated
Updated · The Nation · Aug 13
GLP-1 Patents Generate $60 Billion, Deepening a 100 Million-Person U.S. Treatment Gap
2 articles · Updated · The Nation · Aug 13
Summary
$60 billion to $70 billion in annual GLP-1 revenue is flowing to Novo Nordisk and Eli Lilly even as more than 100 million potential U.S. users remain untreated, framing the drugs as a driver of widening health inequality.
75 cents a month is the estimated manufacturing cost for similar GLP-1s, but Trump administration-backed direct-to-consumer pricing sets starter doses at $299 for Eli Lilly and $350 for Novo Nordisk, with maintenance treatment costing more.
$50 a month is the extra charge in Medicare's GLP-1 pilot, and the fee would not count toward normal out-of-pocket caps; a longer-term plan would apply the cap only after patients pay $245 a month directly.
30 million people already use GLP-1s for weight loss, and researchers see possible uses in liver, heart and kidney disease, some cancers, Alzheimer's and mental illness—raising the stakes of who can afford access.
1% of the wealthiest U.S. counties already outlive working-class rural counties by about 10 years on average, and the report argues a web-based, multi-track drug market could harden that divide into a medical caste system.